Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies

HAB Pharma targets Rs. 3,000 crore revenue by 2030

Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions

Everest Medicines expands Asia-Pacific presence with licensing deal for Bejescin

Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio

Glenmark posts strong FY26 results with 27.5% revenue jump

Manipal Hospital launches ‘Oorja’ Support Group for celiac awareness in children

Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease

HAB Pharma, Signature Phytochemicals merge to form Rs. 600 crore integrated pharma entity

Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026

OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets

The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego

RAG launches lupus patient support group in Ahmedabad

The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments